Non-insulin oral drug(s)-Forxiga (dapagliflozin) Posts on Medivizor
Navigation Menu

Non-insulin oral drug(s)-Forxiga (dapagliflozin) Posts on Medivizor

Do SGLT2 inhibitors reduce heart disease compared to DPP-4 inhibitors?

Do SGLT2 inhibitors reduce heart disease compared to DPP-4 inhibitors?

Posted by on Jul 26, 2020 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effects on heart disease for SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes (T2D). It found that patients using SGLT2 inhibitor medications had lower rates of heart failure, heart attack, and stroke. Some background T2D is a disorder of high levels of glucose (sugar) in the blood. T2D...

Read More

Is the off-label use of type-2 diabetes medications in type 1 diabetes causing increased rates of diabetic ketoacidosis?

Posted by on Dec 9, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study examined the frequency of sodium-glucose cotransporter 2 (SGLT2) inhibitor use in type 1 diabetes (T1D) and the resulting rates of diabetic ketoacidosis (DKA). The study concluded that while the proportion of SGLT2 use in T1D is small, there is a significant associated risk of DKA. Some background There are two...

Read More

Can dapagliflozin help improve blood magnesium levels in patients with Type 2 diabetes?

Posted by on Nov 6, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study examined the effects of dapagliflozin (Forxiga) on blood magnesium levels in patients with type 2 diabetes (T2D). The authors concluded that dapagliflozin treatment helped improve blood magnesium levels in these patients. Some background T2D is associated with a number of other health complications. Patients with T2D...

Read More

Do SGLT2 inhibitors prevent cardiovascular complications in type 2 diabetes?

Posted by on Sep 10, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study investigated whether SGLT2 (sodium-glucose co-transporter-2) inhibitors reduced the risk of cardiovascular complications in patients with type 2 diabetes. They found that SGLT2 inhibitors were associated with reduced risk of cardiovascular disease and mortality compared to other treatment types.  Some background...

Read More